Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10544742 | 0.77 | GRIK1 (0.45) | ABCC4MAPTALOX15HSD17B10GRIK1 | |
| SCHEMBL474963 | 0.77 | — | — | |
| SCHEMBL474965 | 0.77 | — | — | |
| SCHEMBL11138578 | 0.76 | GRIK1 (0.39) | ABCC4MAPTALOX15HSD17B10GRIK1 | |
| SCHEMBL27447898 | 0.74 | ABCC4 (0.34) | ABCC4MAPTALOX15HSD17B10GRIK1 | |
| SCHEMBL29199347 | 0.72 | LDHA (0.40) | MAPTALOX15LDHASRRTSHR | |
| SCHEMBL7649349 | 0.71 | GRIK1 (0.35) | ABCC4MAPTALOX15HSD17B10GRIK1 | |
| SCHEMBL9746694 | 0.70 | — | — | |
| SCHEMBL355795 | 0.70 | LDHA (0.38) | LDHASRRCPA1TSHR | |
| SCHEMBL15467869 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0179254-B1 | 4,5-Dihydro-4-oxo-2- [(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof | PENNWALT CORPORATION (US) | 1989-03-29 | — | — | EP | claimed |
| EP-0179254-A1 | 4,5-Dihydro-4-oxo-2- [(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof | PENNWALT CORPORATION (US) | 1986-04-30 | — | — | EP | claimed |
| US-8334132-B2 | Process for production of a betaine such as carnitine | MITSUBISHI RAYON CO., LTD. (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20090325246-A1 | PROCESS FOR PRODUCTION OF BETAINE | MITSUBISHI RAYON CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2096103-A1 | PROCESS FOR PRODUCTION OF BETAINE | Mitsubishi Rayon Co. Ltd. (JP) | 2009-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325246-A1 | PROCESS FOR PRODUCTION OF BETAINE | BCKDK, CPT1B, CRAT | ABCC4 1394/4885MAPT 4427/4885ALOX15 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.